Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

National and State Vaccination Coverage Among Children Aged 19--35 Months --- United States, 2010

The National Immunization Survey (NIS) monitors vaccination coverage among children aged 19--35 months using a random-digit--dialed sample of telephone numbers of households to evaluate childhood immunization programs in the United States. This report describes the 2010 NIS coverage estimates for children born during January 2007--July 2009. Nationally, vaccination coverage increased in 2010 compared with 2009 for ≥1 dose of measles, mumps, and rubella vaccine (MMR), from 90.0% to 91.5%; ≥4 doses of pneumococcal conjugate vaccine (PCV), from 80.4% to 83.3%; the birth dose of hepatitis B vaccine (HepB), from 60.8% to 64.1%; ≥2 doses of hepatitis A vaccine (HepA), from 46.6% to 49.7%; rotavirus vaccine, from 43.9% to 59.2%; and the full series of Haemophilus influenzae type b (Hib) vaccine, from 54.8% to 66.8%. Coverage for poliovirus vaccine (93.3%), MMR (91.5%), ≥3 doses HepB (91.8%), and varicella vaccine (90.4%) continued to be at or above the national health objective targets of 90% for these vaccines.* The percentage of children who had not received any vaccinations remained low (<1%). For most vaccines, no disparities by racial/ethnic group were observed, with coverage for other racial/ethnic groups in 2010 similar to or higher than coverage among white children. However, disparities by poverty status still exist. Maintaining high vaccination coverage levels is important to reduce the burden of vaccine-preventable diseases and prevent a resurgence of these diseases in the United States, particularly in undervaccinated populations (1).

NIS uses a quarterly, random-digit--dialed sample of telephone numbers to reach households with children aged 19--35 months for the 50 states and selected local areas and territories, followed by a mail survey to the children's vaccination providers to collect vaccination information. Data were weighted to represent the population of children aged 19--35 months, with adjustments for households with multiple telephone lines, household nonresponse, and exclusion of households without landline telephones.§ During 2010, the household response rate was 63.8%; providers returned vaccination records for 71.2% of all children with completed household interviews, for a total of 17,004 children with provider-reported vaccination records included in this report. Because the number of Hib** vaccine and rotavirus†† vaccine doses required differs according to manufacturer, coverage estimates for these vaccines take into account brand of vaccine used. Logistic regression was used to examine differences among racial/ethnic groups, controlling for poverty status. Statistical analyses were conducted using t-tests based on weighted data and accounting for the complex survey design. A p-value of <0.05 was considered statistically significant.

During 2010, national coverage with all recommended vaccines increased or remained stable compared with 2009 (Table 1). Coverage with vaccines with longstanding recommendations has remained stable since the mid-1990s§§ (i.e., diphtheria, tetanus toxoids, and acellular pertussis vaccine [DTaP], poliovirus vaccine, varicella vaccine, and ≥3 doses of HepB). For MMR, after a decrease from 92.1 in 2008 to 90.0 in 2009, coverage with ≥1 dose increased to 91.5% in 2010. Although coverage with the primary series of Hib vaccine remained stable at 92.2%, coverage with the full series (primary series plus booster dose) increased to 66.8% in 2010 from 54.8% in 2009. For the most recently recommended vaccinations, coverage with rotavirus vaccine increased to 59.2% in 2010 from 43.9% in 2009. Within the 2010 sample, rotavirus vaccination coverage increased from 51.9% among children born during January--June 2007 to 69.8% among children born during January--June 2009. Coverage with ≥2 doses of HepA increased to 49.7% in 2010 from 46.6% in 2009, coverage with the first dose of HepB within 3 days of birth (birth dose) increased to 64.1% in 2010 from 60.8% in 2009, and coverage with ≥4 doses of PCV increased to 83.3% in 2010 from 80.4% in 2009. As in 2009, the seven-vaccine series (4:3:1:3:3:1:4)¶¶ reported in 2010 excludes the Hib vaccine because of the Hib vaccine shortage that occurred during December 2007--September 2009 (2,3). Coverage with the modified seven-vaccine series (excluding Hib vaccine) increased to 72.7% in 2010 from 70.5% in 2009 (Table 1).

Coverage varied by race/ethnicity.*** Among black children, coverage with ≥4 doses of PCV and rotavirus vaccine was lower compared with white children (Table 2). Compared with white children, coverage with ≥1 dose of varicella vaccine was higher among black, Hispanic, American Indian/Alaska Native, and Asian children. Also compared with white children, coverage among Hispanic children was higher for ≥1 dose of MMR and ≥2 doses of HepA, and coverage among American Indian/Alaska Native children was higher for the primary and full series of Hib vaccine and ≥3 doses of HepB. With the exception of the difference in coverage between white children and black children for ≥4 doses of PCV, all differences remained statistically significant after controlling for poverty status.

Coverage among children living below poverty level††† was lower than coverage among children living at or above poverty level for ≥3 and ≥4 doses DTaP, the primary and full series of the Hib vaccine, ≥3 and ≥4 doses PCV, rotavirus vaccine, and the 4:3:1:3:3:1:4 series with and without Hib (Table 2). Coverage with the birth dose of HepB was higher among children living below the poverty level compared with children living at or above the poverty level.

Vaccination coverage continued to vary by state, particularly for the more recently recommended vaccinations (Table 3). Coverage with rotavirus vaccine in 2010 significantly increased in 40 states compared with 2009, and coverage ranged from 42.1% in Maine to 82.1% in Delaware. Coverage with ≥2 doses HepA significantly increased in six states compared with 2009, and ranged from 27.2% in Maine to 64.4% in Georgia. Coverage with the birth dose of HepB significantly increased in five states compared with 2009, and ranged from 21.4% in Vermont to 83.3% in Kentucky. Coverage with MMR was greater than 85% in all states. Coverage for the modified vaccine series (4:3:1:3:3:1:4 series excluding Hib) varied by state, from 61.3% in Nevada to 82.7% in Wisconsin.

Reported by

Carla L. Black, PhD, Karen G. Wooten, MA, David Yankey, MS, Maureen Kolasa, MPH, Immunization Svcs Div, National Center for Immunization and Respiratory Diseases, CDC. Corresponding contributor: Carla L. Black, cblack2@cdc.gov, 404-639-8436.

Editorial note

The results of the 2010 NIS indicate that vaccination coverage among children aged 19--35 months remained stable or increased compared with 2009. Coverage levels for poliovirus vaccine, MMR, HepB, and varicella vaccine continue to be at or above 90%, the national health objective target for these vaccines. The record high number of measles cases reported in the United States so far in 2011 (4) underscores the importance of maintaining high MMR coverage to protect from measles importations and transmission in the United States. Nevertheless, room for improvement exists. Nearly one in 10 children has not received MMR by age 19--35 months.

Among the more recently recommended vaccines, coverage continued to increase for ≥4 doses PCV, the birth dose of HepB, and HepA. Coverage with rotavirus vaccine increased 15.3 percentage points, from 43.9% in 2009 to 59.2% in 2010. Although some children in the 2009 NIS sample were born before the 2006 introduction of live rotavirus vaccine and thus were not affected by the recommendation to be vaccinated, the large increase in coverage observed in the 2010 NIS and the trend in increased coverage among successive birth cohorts within the 2010 sample indicate that the recommendation for rotavirus vaccination was successfully implemented in more recent birth cohorts, and coverage likely will continue to increase.

Coverage with the primary series of Hib vaccine remained stable at 92.2%, indicating that during the shortage of Hib vaccine that occurred during December 2007--June 2009, vaccination providers were able to comply with the interim recommendations to defer the booster dose but continue to vaccinate children with the primary series (2). Children in both the 2009 and 2010 NIS samples were affected by the temporary recommendation to suspend the booster dose of Hib vaccine. Coverage with the full series of Hib vaccine increased by 12 percentage points in 2010 compared with 2009, suggesting that children received the booster dose as Hib vaccine supplies became adequate starting in July 2009 (3).

In the 2009 NIS, disparities in coverage between white children and children of other racial/ethnic groups were reported for several of the recommended vaccines (e.g., HepA, PCV, and DTaP) (5). Because of increases in coverage among minority children, the 2010 coverage levels for most vaccines among other racial/ethnic groups were similar to or higher than coverage levels among white children; however, racial/ethnic disparities independent of poverty still remained for rotavirus. Disparities in coverage by poverty level remained for many vaccines. Although the Vaccines for Children Program,§§§ a federal entitlement program that provides vaccine at no cost for eligible children, has been effective in reducing potential gaps in coverage levels resulting from poverty status, the remaining disparities in coverage by poverty status reflect barriers to vaccination that must be addressed.

Vaccination coverage continues to vary across states, especially for the more recently recommended vaccines. Differences by state in factors such as population characteristics, state policies (e.g., child-care vaccination requirements), vaccine financing policies that affect the availability of publicly purchased vaccine, and immunization program activities (e.g., the presence of outreach activities) likely contribute to variations in vaccination coverage (6,7). Further work is needed to understand factors that most strongly influence vaccination coverage and identify best practices among states.

The findings in this report are subject to at least three limitations. First, NIS is a landline-based telephone survey, and statistical adjustments might not fully compensate for nonresponse and households without landline telephones. Previous studies have shown that vaccination coverage estimates that include nonlandline households might be lower than NIS estimates (8). During the fourth quarter, the 2010 NIS sampled telephone numbers from a cellular telephone sampling frame.¶¶¶ Differences between national landline and dual-frame (including households interviewed by landline plus those from the cellular telephone sampling frame) coverage estimates for specific vaccines and series ranged from -1.2 to 2.2 percentage points. Second, underestimates of vaccination coverage might have resulted from the exclusive use of provider-reported vaccination histories because completeness of these records is unknown. Finally, although national coverage estimates are precise, estimates for state and local areas should be interpreted with caution because of smaller sample sizes and wider confidence intervals.

A recent economic analysis of the United States immunization policy indicated that vaccination of each U.S. birth cohort with the current childhood immunization schedule prevents approximately 42,000 deaths and 20 million cases of disease, with net savings of nearly $14 billion in direct costs and $69 billion in total societal costs (1). Although coverage levels for more recently recommended vaccines have continued to increase, the careful monitoring of coverage levels overall and in subpopulations (e.g., by race/ethnicity and geographic area) will be important to ensure that all children are adequately protected. The results of the 2010 NIS indicate that parents and primary-care givers continued to ensure that children were vaccinated, despite temporary suspension of the booster dose of Hib vaccine during 2007--2009 because of a national vaccine shortage (4), heightened public concerns regarding vaccine safety (9), and budget challenges experienced by states (10). The Guide to Community Preventive Services recognizes the effectiveness of continued partnerships among national, state, local, private, and public entities in sustaining vaccination coverage levels and ensuring that coverage levels for the more recently recommended vaccines continue to increase.****

References

  1. CDC. Ten great public health achievements---United States, 2001--2010. MMWR 2011;60:619--23.
  2. CDC. Interim recommendations for the use of Haemophilus influenzae type b (Hib) conjugate vaccines related to the recall of certain lots of Hib-containing vaccines. MMWR 2007;56:1318--20.
  3. CDC. Updated recommendations for use of Haemophilus influenzae type b (Hib) vaccine: reinstatement of the booster dose at ages 12--15 months. MMWR 2009;58:673--4.
  4. CDC. Measles---United States, January--May 20, 2011. MMWR 2011;60:666--8.
  5. CDC. National, state, and local area vaccination coverage among children aged 19--35 months---United States, 2009. MMWR 2010;59:1171--7.
  6. Groom H, Kennedy A, Evans V, Fasano N. Qualitative analysis of immunization programs with most improved childhood vaccination coverage from 2001 to 2004. J Public Health Manag Pract 2010;16:E1--8.
  7. Lee GM, Santoli JM, Hannan C, et al. Gaps in vaccine financing for underinsured children in the United States. JAMA 2007;298:638--43.
  8. Barron M, Wooten K, Taylor B. Comparing vaccination estimates from four survey designs: vaccination estimates from RDD, RDD+cell, ABS, and area probability sampling. Presented at the 2010 Joint Statistical Meetings; July 31--August 5, 2010; Vancouver, British Columbia, Canada.
  9. Chatterjee A, O'Keefe C. Current controversies in the USA regarding vaccine safety. Expert Rev Vaccines 2010;9:497--502.
  10. Association of State and Territorial Health Officials. Budget cuts continue to affect the health of Americans: update May 2011. Available at http://www.astho.org/display/assetdisplay.aspx?id=6024. Accessed August 24, 2011.

* Additional information about the 2010 health objectives is available at http://www.healthypeople.gov/2010/document/html/volume1/14immunization.htm#_toc494510242. Information about the 2020 health objectives is available at http://healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicid=23.

The 11 local areas separately sampled for the 2010 NIS included six areas that receive federal immunization grant funds and are included in the NIS sample every year (District of Columbia; Chicago, Illinois; New York, New York; Philadelphia County, Pennsylvania; Bexar County, Texas; and Houston, Texas) and three previously sampled areas (Los Angeles County, California; Dallas County, Texas; and El Paso County, Texas). Washington is split into eastern counties and western counties (a list of specific counties is available online at http://www.cdc.gov/vaccines/stats-surv/nis/faqs.htm). The territory of the U.S. Virgin Islands (including St. Croix, St. Thomas, St. John, and Water Island) was included in the 2010 NIS sample. Data from the U.S. Virgin Islands are excluded from national coverage estimates.

§ A description of the statistical methodology of NIS is available at http://www.cdc.gov/nchs/data/series/sr_02/sr02_138.pdf.

The Council of American Survey Research Organization (CASRO) household response rate, calculated as the product of the resolution rate (percentage of the total telephone numbers called that were classified as either nonworking, nonresidential, or residential), screening completion rate (percentage of known households that were successfully screened for the presence of age-eligible children), and the interview completion rate (percentage of households with one or more age-eligible children that completed the household survey). Additional information is available at http://casro.org/codeofstandards.cfm.

** Coverage for Hib vaccine for the primary series was based on receipt of ≥2 or ≥3 doses, depending on product type received. The Merck Hib vaccines require a 2-dose primary series with doses at ages 2 months and 4 months, and the Sanofi Pasteur Hib vaccines require a 3-dose primary series with doses at ages 2, 4, and 6 months. Coverage for the full series, which includes the primary series and a booster dose, was based on receipt of ≥3 or ≥4 doses, depending on product type received. Both Merck and Sanofi Pasteur Hib vaccines require a booster dose at ages 12--15 months.

†† Coverage for rotavirus vaccine was based on ≥2 or ≥3 doses, depending on product type received (≥2 doses for Rotarix [RV1], licensed in April 2008, and ≥3 doses for RotaTeq [RV5], licensed in February 2006).

§§ A figure depicting coverage with individual vaccines from the inception of NIS in 1994 through 2010 is available at http://www.cdc.gov/vaccines/stats-surv/nis/nis-2010-released.htm.

¶¶ Includes ≥4 doses of DTP/DT/DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, ≥3 doses of Hib vaccine, ≥3 doses of HepB, ≥1 dose of varicella vaccine, and ≥4 doses of PCV.

*** Race was self-reported. Persons identified as white, black, Asian, or American Indian/Alaska Native are all non-Hispanic. Persons identified as Hispanic might be of any race. Children identified as multiracial selected more than one race category.

††† Poverty status categorizes income into 1) at or above the poverty level and 2) below the poverty level. Poverty level was based on 2009 U.S. Census poverty thresholds, available at http://www.census.gov/hhes/www/poverty.html.

§§§ Additional information is available at http://www.cdc.gov/vaccines/programs/vfc/default.htm.

¶¶¶ Participants were eligible for interview from the cellular-telephone sampling frame if their household was cellular-telephone-only (household with access to a cellular telephone but not a landline telephone) or cellular-telephone-mainly (household containing both a cellular telephone and a landline telephone, but reporting they are not at all likely or are somewhat unlikely to answer the landline telephone if it rang).

**** Additional information available at http://www.thecommunityguide.org/vaccines/universally/index.html.


What is already known on this topic?

To monitor efforts to reduce the burden and prevent a resurgence of vaccine-preventable diseases, the National Immunization Survey (NIS) estimates vaccination coverage among U.S. children aged 19--35 months.

What is added by this report?

Childhood vaccination coverage with the longer-standing recommended vaccines remains at or above national health objective target levels, and coverage with the newly recommended vaccines continues to increase; however, coverage levels vary by state, and disparities in coverage by poverty level still exist.

What are the implications for public health practice?

Continued partnerships among national, state, local, private, and public entities help parents and primary-care givers ensure that children are vaccinated to sustain current coverage levels and ensure that coverage levels for the more recently recommended vaccines continue to increase to reduce the burden of vaccine-preventable diseases and prevent a resurgence of these diseases in the United States.


TABLE 1. Estimated vaccination coverage among children aged 19--35 months, by selected vaccines and dosages --- National Immunization Survey, United States, 2006--2010*

Vaccine

2006

2007

2008

2009

2010

%

(95% CI)

%

(95% CI)

%

(95% CI)

%

(95% CI)

%

(95% CI)

DTP/DT/DTaP

≥3 doses

95.8

(±0.5)

95.5

(±0.5)

96.2

(±0.5)

95.0

(±0.6)

95.0

(±0.6)

≥4 doses

85.2

(±0.9)

84.5

(±0.7)

84.6

(±1.0)

83.9

(±1.0)

84.4

(±1.0)

Poliovirus

92.8

(±0.6)

92.6

(±0.9)

93.6

(±0.6)

92.8

(±0.7)

93.3

(±0.7)

MMR ≥1 dose

92.3

(±0.6)

92.3

(±0.9)

92.1

(±0.7)

90.0

(±0.8)

91.5

(±0.7)

Hib§

≥3 doses

93.4

(±0.6)

92.9

(±0.7)

90.9

(±0.7)

83.6

(±1.0)

90.4

(±0.9)

Primary series

N/A

N/A

N/A

92.1

(±0.8)

92.2

(±0.8)

Full series

N/A

N/A

N/A

54.8

(±1.4)

66.8

(±1.3)

HepB

≥3 doses

93.3

(±0.6)

92.7

(±0.7)

93.5

(±0.7)

92.4

(±0.7)

91.8

(±0.7)

1 dose by 3 days (birth)

50.1

(±1.1)

53.2

(±1.3)

55.3

(±1.3)

60.8

(±1.3)

64.1

(±1.3)

Varicella ≥1 dose

89.2

(±0.7)

90.0

(±0.7)

90.7

(±0.7)

89.6

(±0.8)

90.4

(±0.8)

PCV

≥3 doses

86.9

(±0.8)

90.0

(±1.0)

92.8

(±0.6)

92.6

(±0.7)

92.6

(±0.8)

≥4 doses

68.4

(±1.1)

75.3

(±1.3)

80.1

(±1.1)

80.4

(±1.2)

83.3

(±1.0)

HepA (≥2 doses)**

N/A

N/A

40.4

(±1.2)

46.6

(±1.4)

49.7

(±1.4)

Rotavirus††

N/A

N/A

N/A

43.9

(±1.4)

59.2

(±1.4)

Combined series

4:3:1:3:3:1§§

76.9

(±1.0)

77.4

(±1.1)

76.1

(±1.1)

69.9

(±1.2)

74.9

(±1.2)

4:3:1:3:3:1 with Hib excluded

77.6

(±1.0)

78.3

(±1.1)

78.7

(±1.1)

77.5

(±1.1)

77.8

(±1.1)

4:3:1:3:3:1:4¶¶

60.1

(±1.2)

66.5

(±1.3)

68.4

(±1.2)

63.6

(±1.2)

70.2

(±1.3)

4:3:1:3:3:1:4 with Hib excluded

60.4

(±1.2)

67.0

(±1.3)

70.6

(±1.2)

70.5

(±1.2)

72.7

(±1.2)

Children who received no vaccinations

0.4

(±0.1)

0.6

(±0.1)

0.6

(±0.2)

0.6

(±0.1)

0.7

(±0.2)

Abbreviations: CI = confidence interval; DTP/DT/DTaP = diphtheria, tetanus toxoids, and pertussis vaccine; diphtheria and tetanus toxoids vaccine; and diphtheria, tetanus toxoids, and acellular pertussis vaccine; MMR = measles, mumps, and rubella vaccine; Hib = Haemophilus influenzae type b vaccine; HepB = hepatitis B vaccine; HepA = hepatitis A vaccine; N/A = not available; PCV = pneumococcal conjugate vaccine.

* For 2006, includes children born during January 2003--June 2005; for 2007, children born during January 2004--July 2006; for 2008, children born during January 2005--June 2007; for 2009, children born during January 2006--July 2008; and for 2010, children born during January 2007--July 2009.

Statistically significant increase in coverage compared with 2009 (p<0.05).

§ Primary series: receipt of ≥2 or ≥3 doses, depending on product type received. Full series: receipt of ≥3 or ≥4 doses, depending on product type received (primary series and booster dose). Hib coverage for primary or full series not available until 2009.

HepB administered between birth and age 3 days.

** HepA coverage not available before 2008.

†† Rotavirus vaccine includes ≥2 or ≥3 doses, depending on the product type received (≥2 doses for Rotarix [RV1] and ≥3 doses for RotaTeq [RV5]). Estimates of rotavirus vaccination coverage not available before 2009.

§§ 4:3:1:3:3:1 series, referred to as routine, includes ≥4 doses of DTP/DT/DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, ≥3 doses of Hib, ≥3 doses of HepB, and ≥1 dose of varicella vaccine.

¶¶ 4:3:1:3:3:1:4 series, referred to as routine, includes ≥4 doses of DTP/DT/DTaP, ≥3 doses of poliovirus vaccine, ≥1 doses of measles-containing vaccine, ≥3 doses of Hib vaccine, ≥3 doses of HepB, ≥1 dose of varicella vaccine, and ≥4 doses of PCV. Beginning in 2011, in accordance with the Healthy People 2020 objectives, the routine series will replace ≥3 doses of Hib vaccine with the full series of Hib vaccine (receipt of ≥3 or ≥4 doses, depending on product type).


TABLE 2. Estimated vaccination coverage among children aged 19--35 months, by selected vaccines and dosages, race/ethnicity,* and poverty level--- National Immunization Survey, United States, 2010§

Vaccine

Race/Ethnicity

Poverty level

White, non-Hispanic

Black, non-Hispanic

Hispanic

American Indian/Alaska Native

Asian

Multiracial, non-Hispanic

Below

At or above

%

(95% CI)

%

(95% CI)

%

(95% CI)

%

(95% CI)

%

(95% CI)

%

(95% CI)

%

(95% CI)

%

(95% CI)

DTP/DT/DTaP

≥3 doses

95.1

(±0.8)

95.3

(±1.6)

95.1

(±1.4)

97.3

(±2.2)

95.7

(±2.9)

92.4

(±3.5)

93.5

(±1.4)

95.7

(±0.7)

≥4 doses

84.5

(±1.3)

83.7

(±2.7)

84.4

(±2.5)

81.8

(±7.5)

88.3

(±4.0)

82.8

(±4.8)

80.8

(±2.2)

86.1

(±1.2)

Poliovirus

93.2

(±0.8)

94.0

(±1.6)

93.8

(±1.6)

94.6

(±3.5)

92.8

(±3.5)

90.2

(±3.9)

92.4

(±1.5)

93.6

(±0.8)

MMR ≥1 dose

90.6

(±0.9)

92.1

(±1.9)

92.9

(±1.6)**

93.4

(±6.3)

91.7

(±3.6)

89.7

(±3.8)

91.3

(±1.6)

91.4

(±0.8)

Hib††

≥3 doses

90.3

(±1.2)

89.4

(±2.3)

92.0

(±1.7)

93.9

(±3.0)**

85.7

(±5.7)

87.3

(±4.4)

88.1

(±1.8)

91.4

(±1.0)

Primary series

92.3

(±1.1)

90.9

(±2.2)

93.3

(±1.5)

95.7

(±2.7)**

89.0

(±5.3)

90.4

(±3.8)

89.8

(±1.7)

93.4

(±0.9)

Full series

67.5

(±1.6)

65.4

(±3.4)

64.8

(±3.1)

77.1

(±7.4)**

69.5

(±6.8)

70.1

(±5.8)

61.3

(±2.7)

69.7

(±1.5)

HepB

≥3 doses

91.4

(±0.9)

92.1

(±1.8)

92.5

(±1.7)

97.2

(±2.3)**

91.7

(±3.5)

89.9

(±3.8)

91.5

(±1.5)

92.0

(±0.8)

1 dose by 3 days (birth)§§

63.2

(±1.6)

64.1

(±3.6)

65.5

(±3.1)

71.9

(±9.6)

62.6

(±7.2)

64.4

(±6.4)

67.2

(±2.7)

62.8

(±1.6)

Varicella ≥1 dose

88.9

(±1.1)

91.5

(±2.0)**

92.3

(±1.8)**

95.7

(±2.7)**

92.5

(±3.4)**

88.9

(±3.9)

89.6

(±1.8)

90.6

(±0.9)

PCV

≥3 doses

92.8

(±0.9)

92.6

(±2.0)

93.4

(±1.8)

94.5

(±3.0)

87.8

(±5.4)

90.6

(±3.8)

91.1

(±1.6)

93.5

(±0.9)

≥4 doses

84.2

(±1.2)

79.7

(±3.0)**

83.9

(±2.3)

85.3

(±5.0)

78.9

(±6.0)

83.0

(±4.7)

78.7

(±2.2)

85.6

(±1.1)

HepA (≥2 doses)

45.8

(±1.6)

48.6

(±3.7)

57.0

(±3.1)**

NA¶¶

50.8

(±7.5)

49.8

(±6.6)

51.0

(±2.7)

49.1

(±1.6)

Rotavirus***

60.2

(±1.7)

52.7

(±3.6)**

60.5

(±3.2)

NA¶¶

62.6

(±7.0)

57.7

(±6.5)

51.5

(±2.7)¶

62.9

(±1.6)

Combined series

4:3:1:3:3:1†††

73.6

(±1.5)

74.5

(±3.1)

77.2

(±2.7)**

77.2

(±7.8)

74.4

(±6.3)

75.8

(±5.3)

73.5

(±2.4)

75.5

(±1.4)

4:3:1:3:3:1 with Hib excluded

76.7

(±1.4)

77.4

(±3.0)

79.4

(±2.7)

78.7

(±7.7)

81.4

(±4.8)

78.4

(±5.1)

76.2

(±2.3)

78.5

(±1.3)

4:3:1:3:3:1:4§§§

69.9

(±1.6)

66.9

(±3.4)

72.0

(±2.9)

73.1

(±8.1)

67.3

(±6.7)

73.0

(±5.4)

67.2

(±2.5)

71.6

(±1.5)

4:3:1:3:3:1:4 with Hib excluded

72.7

(±1.5)

69.3

(±3.4)

74.1

(±2.8)

74.5

(±8.1)

70.2

(±6.5)

75.6

(±5.2)

69.5

(±2.5)

74.3

(±1.4)

Abbreviations: CI = confidence interval; DTP/DT/DTaP = diphtheria, tetanus toxoids, and pertussis vaccine; diphtheria and tetanus toxoids vaccine; and diphtheria, tetanus toxoids, and acellular pertussis vaccine; MMR = measles, mumps, and rubella vaccine; Hib = Haemophilus influenzae type b vaccine; HepB = hepatitis B vaccine; HepA = hepatitis A vaccine; N/A = not available; PCV = pneumococcal conjugate vaccine.

* Native Hawaiian or other Pacific Islanders were not included because of small sample sizes.

Poverty level was determined for all children. Children were classified as below poverty if their total family income was less than the poverty threshold specified for the applicable family size and number of children aged <18 years. All others were classified as at or above poverty. Poverty thresholds reflect yearly changes in the Consumer Price Index. Thresholds and guidelines available at http://www.census.gov/hhes/www/poverty.html.

§ Children in the 2010 National Immunization Survey were born during January 2007--July 2009.

Estimates are statistically significant at p<0.05. Children living at or above poverty were the reference group.

** Estimates are statistically significant at p<0.05. Non-Hispanic white children were the reference group.

†† Primary series: receipt of ≥2 or ≥3 doses, depending on product type received; full series: primary series and booster dose includes receipt of ≥3 or ≥4 doses depending on product type received.

§§ HepB administered between birth and age 3 days.

¶¶ Estimate not available if the unweighted sample size for the denominator was <30 or CI half width / estimate >0.588 of CI half width >10.

*** Includes ≥2 or ≥3 doses, depending on product type received (≥2 doses for Rotarix [RV1] and ≥3 doses for RotaTeq [RV5]).

††† 4:3:1:3:3:1 series includes ≥4 doses of DTP/DT/DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, ≥3 doses of Hib, ≥3 doses of HepB, and ≥1 dose of varicella vaccine.

§§§ 4:3:1:3:3:1:4 series includes ≥4 doses of DTP/DT/DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, ≥3 doses of Hib, ≥3 doses of HepB, ≥1 dose of varicella vaccine, and ≥4 doses of PCV.


TABLE 3. Estimated vaccination coverage for vaccination series (modified)* and selected individual vaccines among children aged 19--35 months, by state and local area --- National Immunization Survey, United States, 2010

State/Area

MMR (≥1 dose)

PCV (≥4 doses)

HepB (birth)§

HepA (≥2 doses)

Rotavirus**

Vaccine series (modified)*

%

(95% CI)

%

(95% CI)

%

(95% CI)

%

(95% CI)

%

(95% CI)

%

(95% CI)

United States

91.5

(±0.7)††

83.3

(±1.0)††

64.1

(±1.3)††

49.7

(±1.4)††

59.2

(±1.4)††

72.7

(±1.2)††

Alabama

95.4

(±2.3)

86.1

(±4.1)††

70.7

(±5.5)

50.5

(±6.2)

63.4

(±6.1)††

72.4

(±5.5)

Alaska

88.4

(±3.9)

75.7

(±5.9)

71.2

(±6.0)

44.7

(±6.8)

47.1

(±6.8)††

66.1

(±6.5)

Arizona

87.7

(±4.9)

79.9

(±5.9)

80.4

(±5.2)

51.0

(±6.7)

60.7

(±6.7)††

71.1

(±6.3)

Arkansas

90.5

(±4.2)††

79.5

(±5.8)††

82.4

(±5.0)††

34.2

(±6.4)††

48.5

(±7.0)††

74.5

(±6.0)††

California

91.4

(±3.5)

83.5

(±4.8)

53.0

(±6.7)

53.4

(±6.7)

58.9

(±6.7)††

71.0

(±6.0)

Los Angeles County

93.0

(±3.1)

89.0

(±4.3)††

52.3

(±7.3)

52.6

(±7.2)

65.1

(±7.0)††

78.1

(±5.8)

Rest of state

90.8

(±4.6)

81.5

(±6.4)

53.2

(±8.8)

53.7

(±8.7)

56.6

(±8.8)††

68.4

(±7.9)

Colorado

89.3

(±3.7)

81.6

(±5.4)

57.6

(±7.0)

42.0

(±6.7)

55.0

(±7.3)

68.3

(±6.4)

Connecticut

97.8

(±1.5)††

91.1

(±4.4)

60.0

(±7.7)††

48.5

(±7.7)

61.8

(±7.8)††

79.4

(±6.1)

Delaware

94.0

(±3.0)

87.9

(±4.3)

69.3

(±5.7)

62.0

(±6.0)††

82.1

(±4.8)††

71.9

(±5.7)

District of Columbia

94.7

(±3.7)

88.0

(±5.4)††

63.5

(±7.9)

55.8

(±8.1)

52.7

(±8.3)††

78.8

(±6.5)††

Florida

94.1

(±3.0)

88.1

(±4.9)††

52.3

(±7.9)

49.6

(±7.9)

59.7

(±7.8)††

80.5

(±5.8)††

Georgia

91.5

(±4.0)

86.3

(±5.5)

74.9

(±5.8)

64.4

(±6.7)

59.0

(±6.8)††

74.7

(±6.3)

Hawaii

93.2

(±3.3)††

83.0

(±5.3)

71.5

(±6.0)

44.9

(±6.4)

52.1

(±6.5)††

76.0

(±5.8)

Idaho

87.2

(±5.0)

79.7

(±5.5)

65.2

(±6.4)

44.2

(±6.8)

50.4

(±6.9)††

66.3

(±6.4)

Illinois

90.5

(±3.2)

87.1

(±4.0)

66.1

(±5.2)

45.2

(±5.5)

60.3

(±5.5)††

75.1

(±4.9)

City of Chicago

88.8

(±3.8)

88.9

(±3.8)

74.6

(±5.6)

44.1

(±6.6)

61.8

(±6.5)††

75.1

(±5.4)

Rest of state

91.1

(±4.2)

86.5

(±5.2)

63.1

(±6.7)

45.6

(±7.1)††

59.8

(±7.0)††

75.1

(±6.3)

Indiana

92.3

(±3.5)

80.2

(±5.3)

77.9

(±5.1)

46.9

(±6.5)

54.3

(±6.3)

71.6

(±5.8)

Iowa

93.8

(±3.7)

87.6

(±5.4)

52.3

(±7.2)

55.8

(±7.2)

66.1

(±6.9)††

77.8

(±6.3)

Kansas

90.0

(±4.6)

85.3

(±5.1)

80.1

(±5.5)

49.7

(±7.4)

58.9

(±7.4)††

78.6

(±6.0)

Kentucky

89.5

(±4.1)

77.7

(±6.0)

83.3

(±4.9)

45.6

(±6.4)

57.5

(±6.7)††

68.9

(±6.4)

Louisiana

89.7

(±4.5)

84.3

(±6.0)

61.6

(±7.8)

51.4

(±7.7)

57.9

(±7.9)

70.9

(±7.2)

Maine

90.9

(±4.5)

81.6

(±6.3)

72.0

(±6.5)

27.2

(±6.6)

42.1

(±7.7)††

72.7

(±7.3)

Maryland

90.5

(±4.8)

75.6

(±7.0)

69.0

(±7.0)

46.0

(±7.4)

53.4

(±7.5)

65.9

(±7.4)§§

Massachusetts

92.3

(±4.3)

90.4

(±4.2)

67.3

(±6.5)

51.1

(±7.3)

70.9

(±6.4)††

78.1

(±6.1)

Michigan

91.1

(±3.8)

88.1

(±4.9)

80.3

(±5.6)

45.0

(±7.2)

54.3

(±7.2)

81.3

(±5.5)

Minnesota

92.7

(±4.0)

88.7

(±4.9)

46.8

(±7.4)††

49.3

(±7.4)

67.4

(±7.2)††

75.7

(±6.4)

Mississippi

93.8

(±2.7)

84.3

(±4.5)

69.1

(±6.0)

40.7

(±6.3)

56.9

(±6.3)††

77.9

(±5.1)

Missouri

90.4

(±3.9)

76.2

(±5.6)

64.8

(±6.5)

44.4

(±6.5)††

59.3

(±6.4)††

67.9

(±6.0)††

Montana

85.1

(±5.6)

72.6

(±6.5)

67.8

(±6.4)

35.5

(±6.6)

54.9

(±6.9)††

64.9

(±6.8)

Nebraska

94.2

(±3.3)

90.4

(±4.2)††

66.7

(±6.9)††

60.3

(±7.1)

73.2

(±6.6)††

79.9

(±5.8)††

Nevada

87.0

(±5.2)

70.8

(±6.8)

66.6

(±6.9)

54.8

(±7.3)

49.4

(±7.2)††

61.3

(±7.2)

New Hampshire

95.8

(±3.0)

93.2

(±4.0)††

62.8

(±7.8)

59.7

(±8.2)

73.1

(±7.3)††

81.0

(±6.5)

New Jersey

86.1

(±5.7)

82.4

(±6.2)

37.2

(±6.7)

40.8

(±6.9)

53.9

(±7.1)††

62.6

(±7.0)

New Mexico

88.8

(±3.8)

78.2

(±5.5)

60.0

(±6.3)

51.1

(±6.6)††

53.9

(±6.6)††

68.3

(±6.1)

New York

89.3

(±3.6)

72.8

(±5.2)§§

50.5

(±5.5)

37.7

(±5.4)

48.5

(±5.5)††

64.1

(±5.4)

City of New York

89.3

(±5.2)

67.6

(±7.7)

45.5

(±7.8)

34.8

(±7.6)

40.7

(±7.6)

59.4

(±7.8)

Rest of state

89.4

(±5.1)

77.7

(±6.9)

55.3

(±7.7)

40.6

(±7.7)

56.0

(±7.8)††

68.7

(±7.5)

North Carolina

94.5

(±2.9)

87.5

(±4.3)

75.0

(±5.8)

48.1

(±6.5)

69.6

(±6.2)††

77.1

(±5.4)

North Dakota

92.6

(±3.5)

89.4

(±4.2)

79.5

(±5.6)

61.1

(±6.5)

73.4

(±6.1)††

79.8

(±5.4)

Ohio

93.6

(±3.5)

81.8

(±6.3)

73.5

(±7.1)

46.2

(±8.1)

57.2

(±8.3)

76.2

(±6.6)

Oklahoma

91.0

(±5.0)

74.5

(±6.4)

66.4

(±6.0)

56.6

(±6.8)

44.4

(±6.6)††

62.9

(±6.5)

Oregon

92.8

(±3.3)

87.7

(±4.4)

61.7

(±6.4)

55.6

(±6.8)

52.8

(±6.9)††

73.4

(±5.9)

Pennsylvania

92.3

(±2.9)

87.2

(±3.5)

71.5

(±5.4)

54.8

(±5.6)

66.1

(±5.6)

77.1

(±4.6)††

Philadelphia County

93.5

(±3.2)

83.5

(±5.2)

72.9

(±6.2)

54.6

(±7.3)

66.5

(±6.9)††

71.2

(±6.4)

Rest of state

92.1

(±3.4)

87.9

(±4.0)

71.2

(±6.3)

54.8

(±6.5)

66.0

(±6.6)

78.2

(±5.3)

Rhode Island

95.8

(±2.7)††

82.3

(±6.9)

69.7

(±7.5)

54.2

(±8.1)

76.7

(±7.3)

74.1

(±7.4)

South Carolina

91.7

(±3.3)

88.1

(±4.1)††

67.4

(±6.3)

47.4

(±6.6)

62.9

(±6.5)††

76.9

(±5.4)

South Dakota

92.1

(±3.6)

76.4

(±6.1)

62.4

(±6.8)

33.1

(±6.6)§§

46.8

(±6.9)

67.0

(±6.7)

Tennessee

93.9

(±3.3)

84.3

(±5.2)

55.3

(±6.8)

59.9

(±6.7)††

65.9

(±6.7)††

77.8

(±5.7)

Texas

91.8

(±2.4)

83.0

(±3.3)

69.6

(±4.2)

54.9

(±4.4)

61.9

(±4.4)††

70.9

(±4.1)

Bexar County

94.6

(±2.8)††

79.5

(±6.0)

63.2

(±6.8)

53.5

(±7.0)

62.0

(±7.1)††

73.7

(±6.5)

City of Houston

93.8

(±3.8)††

83.6

(±5.4)

63.6

(±6.8)

60.0

(±6.7)

64.4

(±6.1)††

73.2

(±6.1)

Dallas County

91.1

(±4.0)

78.2

(±6.1)

66.9

(±6.6)

51.2

(±7.2)

59.2

(±7.2)††

69.3

(±6.8)

El Paso County

87.0

(±5.4)

77.4

(±6.6)

78.7

(±6.3)

61.2

(±7.4)

66.3

(±7.5)††

67.0

(±7.2)

Rest of state

91.6

(±3.4)

84.3

(±4.7)

71.3

(±5.9)

54.3

(±6.3)

61.7

(±6.3)††

70.6

(±5.8)

See table footnotes on page 1161.


TABLE 3. (Continued) Estimated vaccination coverage for vaccination series (modified)* and selected individual vaccines among children aged 19--35 months, by state and local area --- National Immunization Survey, United States, 2010

State/Area

MMR (≥1 dose)

PCV (≥4 doses)

HepB (birth)§

HepA (≥2 doses)

Rotavirus**

Vaccine series (modified)*

%

(95% CI)

%

(95% CI)

%

(95% CI)

%

(95% CI)

%

(95% CI)

%

(95% CI)

Utah

85.5

(±5.1)

78.7

(±5.9)

79.8

(±5.6)

49.6

(±7.0)

65.6

(±6.7)††

69.5

(±6.4)

Vermont

92.7

(±3.3)

84.2

(±5.6)

21.4

(±5.9)

38.0

(±6.8)

51.8

(±7.1)††

69.7

(±6.6)††

Virginia

92.3

(±3.5)

84.9

(±4.8)

58.3

(±6.7)

50.0

(±6.8)††

66.9

(±6.2)††

72.8

(±6.0)

Washington

89.8

(±3.6)

82.9

(±4.4)

77.3

(±4.9)

44.9

(±6.0)

50.4

(±5.9)††

71.2

(±5.5)

Eastern counties

89.2

(±4.7)

83.6

(±5.8)

76.0

(±6.5)

50.2

(±7.7)

49.5

(±7.7)

73.7

(±6.7)

Western counties

90.0

(±4.5)

82.7

(±5.5)

77.7

(±6.1)

43.3

(±7.5)

50.7

(±7.4)

70.4

(±6.9)

West Virginia

92.0

(±3.4)

74.3

(±5.9)

66.7

(±5.9)††

54.0

(±6.5)

51.0

(±6.5)

64.1

(±6.3)

Wisconsin

93.2

(±3.3)

88.4

(±4.9)

61.4

(±6.9)

52.1

(±7.0)

64.7

(±6.9)††

82.7

(±5.2)

Wyoming

92.5

(±3.6)

79.6

(±6.2)

58.4

(±7.3)

33.5

(±6.8)

53.5

(±7.5)††

64.7

(±7.3)

U.S. Virgin Islands

72.6

(±7.8)

57.0

(±8.2)

77.7

(±7.2)

14.0

(±6.1)

19.8

(±7.5)††

45.6

(±8.2)

Abbreviations: MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine; HepB = hepatitis B vaccine; HepA = hepatitis A vaccine; CI = confidence interval.

* Includes ≥4 doses DTP/DT/DTaP vaccine (diphtheria, tetanus toxoids, and pertussis vaccine; diphtheria and tetanus toxoids vaccine; and diphtheria, tetanus toxoids, and acellular pertussis vaccine), ≥3 doses of poliovirus vaccine, ≥1 dose of any measles-containing vaccine, ≥3 doses of HepB, ≥1 dose of varicella vaccine, and ≥4 doses of PCV. Haemophilus influenzae type b vaccine is excluded.

Children in the 2010 National Immunization Survey were born during January 2007--July 2009.

§ ≥1 dose of HepB administered between birth and age 3 days.

≥2 doses HepA and measured among children aged 19--35 months.

** ≥2 or ≥3 doses of rotavirus vaccine, depending on product type received (≥2 doses for Rotarix [RV1] and ≥3 doses for RotaTeq [RV5]).

†† Statistically significant increase in coverage compared with 2009 (p<0.05).

§§ Statistically significant decrease in coverage compared with 2009 (p<0.05).



Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.


All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

 
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #